GLP-1 receptor agonist

ApprovedSmall molecule

Boehringer Ingelheim

GLP-1 receptor agonist is one of 240 small molecule programs targeting Insulin Secretion. It is currently in Approved.

Indications

Total Trials

Active Trials

239

Competitors

Pipeline

Status by Indication[3][1]

Indication

Insulin SecretionActive, not recruiting

Weight LossActive, not recruiting

Diabetes MellitusActive, not recruiting

Polycystic Ovary SyndromeNot yet recruiting

Type 2 DiabetesActive, not recruiting

ObesityActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

Insulin SecretionApproved

Active, not recruiting

Weight LossPreclinical

Active, not recruiting

Diabetes MellitusPreclinical

Active, not recruiting

Polycystic Ovary SyndromePreclinical

Not yet recruiting

Type 2 DiabetesPhase 3

Active, not recruiting

ObesityPreclinical

Active, not recruiting

Chronic Kidney DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

GLP-1 receptor agonist

Boehringer Ingelheim

Approved

5 2

Byetta

AstraZeneca

Preclinical

55 3

Jardiance

Boehringer Ingelheim

Preclinical

31 4

NOVOLIN R

Novo Nordisk

Preclinical

5 5

Glargine

Eli Lilly

Preclinical

8 6

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 7

Aurlumyn

BBTG International Inc.

Preclinical

1 8

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 9

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 10

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Active, not recruiting

Diabetes Mellitus, Type 2

NCT03363464

N/ARecruiting

Postmenopausal Women

NCT06715514

Q1 2027

Recruiting

Weight Loss

NCT07115069

Q4 2027

N/ANot yet recruiting

Obesity

NCT06775093

Q1 2028

N/ARecruiting

Gene Polymorphism

NCT06256419

Clinical

Trials by Indication[1]

Type 2 Diabetes5 trials

A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes

Completed·GGRADE Study Group·Phase 3·NCT01794143·7,850 enrolled

Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes

Completed·AAzienda Ospedaliero-Universitaria Consorziale Policlinico di Bari··NCT06120556·130 enrolled

Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy

Completed·PPegBio Co., Ltd.·Phase 3·NCT04504396·620 enrolled

Show 2 more trials

PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

Recruiting·—·Phase 4·NCT05390892·6,000 enrolled

Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin

Unknown status·—··NCT04034524·20,000 enrolled

GLP-13 trials

Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD

Recruiting·—··NCT07309094·250 enrolled

Effect of GLP-1 Receptor Agonists on Trabecular Bone Score

Terminated·UUniversity of Mississippi Medical Center·Phase 2·NCT04964388·5 enrolled

Impact GLP-1 Agonists Following Bariatric

Recruiting·UUniversity of Missouri-Columbia·Phase 4·NCT06132477·150 enrolled

Gene Polymorphism2 trials

Effect of Gene Polymorphisms on GLP-1 Receptor Agonists Response in Patients With T2DM

Completed·TThe Affiliated Hospital of Xuzhou Medical University·N/A·NCT05037045·338 enrolled

Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM

Recruiting·TThe Affiliated Hospital of Xuzhou Medical University·N/A·NCT06256419·300 enrolled

Chronic Kidney Disease1 trial

Impact of GLP-1 RAs Compared to Basal Insulin Start in Patients Living With Type 2 Diabetes and Chronic Kidney Disease

Completed·LLMC Diabetes & Endocrinology Ltd.··NCT06236672·348 enrolled

Medication1 trial

BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes

Unknown status·—··NCT05161429·550,000 enrolled

16 more indications

Insulin Secretion1 trial

Relationship Between Improvement in Insulin Secretion and Decrease in HbA1c in GLP-1 RA Therapy in T2DM Patients

Unknown status·DDasman Diabetes Institute·Phase 4·NCT04135287·315 enrolled

Diabetes Mellitus1 trial

SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY.

Completed·JJose Seijas Amigo··NCT05136287·140 enrolled

Postmenopausal Women1 trial

Menopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Diabetes

Recruiting·LLia Bally·N/A·NCT06715514·96 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects

Completed·PPegBio Co., Ltd.·Phase 3·NCT04504370·273 enrolled

Cardiovascular1 trial

Cardiovascular and Endothelial Markers During OGTT Before and at Six and Twelve Months Post-treatment in Women With PCOS

Recruiting·—··NCT06889454·120 enrolled

Metabolism1 trial

Bone Metabolism in 12-21 Year Olds Undergoing GLP-1 Receptor Agonist Therapy

Recruiting·UUniversity of Virginia··NCT06903923·120 enrolled

Sts1 trial

Glucagon-like Peptide 1 (GLP1) Receptor Agonists and Mental Health

Unknown status·KKing's College London··NCT05492305·20 enrolled

Total Neoadjuvant Therapy1 trial

Evaluating the Impact of GLP-1 Receptor Agonists With Total Neoadjuvant Therapy in Rectal Cancer

Not yet recruiting·SSt. James's Hospital, Ireland·Phase 2·NCT07314528·42 enrolled

Obesity1 trial

Effects of GLP-1RAs on Reproductive Outcomes in PCOS and Obesity

Not yet recruiting·PPeking University Third Hospital·N/A·NCT06775093·392 enrolled

Weight loss1 trial

Comparison of Body Composition Changes With Weight Loss Interventions

Recruiting·VVanderbilt University Medical Center··NCT07115069·60 enrolled

SGLT-2 Inhibitor1 trial

Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists

Completed·UUniversity of Padova··NCT04184947·10,000 enrolled

Microbiota1 trial

Effects of Diabetes Medications on Adrenal Function and Intestinal Microbiota

Completed·UUniversity of Tartu··NCT04151849·23 enrolled

NAFLD1 trial

Effect of Glucagon-like Peptide -1 Receptor Agonist on Liver Tissue and Plasma Lipids in MASLD

Withdrawn·MMedical College of Wisconsin··NCT06982378

Diabetes Mellitus, Type 21 trial

EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) Study Program

Active, not recruiting· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT03363464·230,000 enrolled

Polycystic Ovary Syndrome1 trial

Effects of GLP-1 Receptor Agonists Combined With Healthy Lifestyle Education Prior to Fertility Treatment on Reproductive Outcomes in Obese Women With Polycystic Ovary Syndrome

Not yet recruiting·PPeking University Third Hospital·Preclinical·NCT07687667·406 enrolled

Cardiovascular-kidney-metabolic Syndrome1 trial

Associations of Early Add-On GLP-1 Receptor Agonist and SGLT2 Inhibitor Therapy With Mortality and Kidney Outcomes in Adults With Obesity and Type 2 Diabetes Across Cardiovascular-Kidney-Metabolic Stages 2-3: A Target-Trial Emulation

Completed·CChung Shan Medical University··NCT07465926·451,036 enrolled

Sources

References

[1]
ClinicalTrials.gov — 28 trial records for GLP-1 receptor agonist. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GLP-1 receptor agonist compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GLP-1 receptor agonist. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Boehringer Ingelheim

GLP-1 receptor agonist

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q1 2027

Q4 2027

Q1 2028

Trials by Indication[1]

Type 2 Diabetes5 trials

GLP-13 trials

Gene Polymorphism2 trials

Chronic Kidney Disease1 trial

Medication1 trial

Insulin Secretion1 trial

Diabetes Mellitus1 trial

Postmenopausal Women1 trial

Safety and Efficacy1 trial

Cardiovascular1 trial

Metabolism1 trial

Sts1 trial

Total Neoadjuvant Therapy1 trial

Obesity1 trial

Weight loss1 trial

SGLT-2 Inhibitor1 trial

Microbiota1 trial

NAFLD1 trial

Diabetes Mellitus, Type 21 trial

Polycystic Ovary Syndrome1 trial

Cardiovascular-kidney-metabolic Syndrome1 trial

References

Drug Info

Quick Facts

Related News